Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Different Drug Formulations

Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Different Drug Formulations

In this paper, two new reversed-phase (RP) HPLC-UV methods enabling the quantitative achiral and chiral analysis of ruxolitinib in commercial tablets (containing 20 mg of active pharmaceutical ingredient, API) and not commercially available galenic capsules (with 5 mg of API) are described. For the...

Full description

Bibliographic Details
Main Authors: Alessandro Di Michele, Aurélie Schoubben, Ina Varfaj, Alessandro D’Arpino, Laura Mercolini, Roccaldo Sardella, Maurizio Ricci, Enrico Tiacci
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Separations
Subjects:
chiral chromatography
COVID-19
enantioseparation
ICH guidelines
pharmaceutical formulations
quantitative analysis
Online Access:https://www.mdpi.com/2297-8739/7/3/47

Internet

https://www.mdpi.com/2297-8739/7/3/47

Similar Items